Prevention of Steroid-associated Osteonecrosis by XLGB: A Clinical Trial for Efficacy and Safety

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-PRC-09000583

Enrollment

Unknown

Registered

2009-11-11

Start date

2007-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

steroid-associated osteonecrosis

Interventions

Group B:4 placebo capsules bid

Group A:4 XLGB capsules bid

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients treated with large dose steroid, including >2000mg prednisone within three months, or >6 tablets of prednisone (5mg/tablet) during initial administration for 1 month, or >=800mg methylprednisolone/day for three days.

Exclusion criteria

Exclusion criteria: 1. Serious primary disease; 2. Diagnosed as femoral head necrosis during MRI examination; 3. Pregnant women; 4. Allergic to drugs; 5. Serious cardiovascular and cerebrovascular diseases, liver or kidney dysfunction, serious hematopoietic system, hematopoietic system, mental disorders, central nervous system, serious hemorrhagic tendency and others.

Design outcomes

Primary

Measure	Time frame
MRI;	—

Secondary

Measure	Time frame
Liver function;Physical examination on hip joint;Kidney function;Fibrinolysis function;Coagulation function;	—

Countries

China

Contacts

Public ContactZirong Li

LZR96@hotmail.com+86 10 64221122-2331

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026